Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Progress Report: EAMS A Limited Success But Could Do Better

Executive Summary

The UK's Early Access to Medicines Scheme (EAMS) has been operational for two years, along with a "promising innovative medicine" (PIM) designation, to give patients timely access to new drugs for serious diseases before they are approved. The system has now been independently reviewed and Scrip talks to those in the industry that have first-hand experience of the process.

Advertisement

Related Content

Brexit Vote Dismays UK Pharma, Triggers Calls To Leverage NHS As Offset
First UK patients to get Merck's Keytruda after landmark early access decision
BMS Opdivo designation a boost for UK early access scheme
10 questions on UK's early access scheme answered
UK industry welcomes early access scheme, but says funding gap could limit interest

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel